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A signiﬁcant increase in life expectancy in successive birth cohorts of people with cystic ﬁbrosis (CF) is a result of more effective treatment for
the disease. It is also now widely recognized that outcomes for patients cared for in specialist CF Centres are better than for those who are not. Key
to the effectiveness of the specialist CF Centre is the multidisciplinary team (MDT), which should include consultants, clinical nurse specialist,
microbiologist, physiotherapist, dietitian, pharmacist, clinical psychologist, social worker, clinical geneticist and allied healthcare professionals, all
of whom should be experienced in CF care. Members of the MDT are also expected to keep up to date with developments in CF through continued
professional development, attendance at conferences, auditing and involvement in research. Specialists CF Centres should also network with other
Centres both nationally and internationally, and feed Centre data to registries in order to further the understanding of the disease. This paper
provides a framework for the specialist CF Centre, including the organisation of the Centre and the individual roles of MDT members, as well as
highlighting the value of CF organisations and disease registries.
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People with cystic fibrosis (CF) have complex care needs that
demand specialist, medical and allied healthcare expertise. The
life expectancy has increased significantly in successive patient
birth cohorts [1] as a result of more effective treatments and
crucially because most patients attend CF Centres in line with the
demonstration that patients who attend CF Centres for their care
have better well-being and lung function than those who do not
[2,3]. Thus, the CF Centre has become the model of care for
people with CF; patients should receive full care from the Centre
or have local directed care supervised by the Centre [4–6].
The framework of the CF Centre is formed by a multi-
disciplinary team (MDT), links with other medical and surgical
specialties, the buildings and facilities, and the hardware
and software that combined allow the MDT to provide a level of
care that meets the complex medical challenges of this disease
using effective diagnostics and holistic treatment programmes.
The MDT members are at the core of the CF Centre and
should be supported with continuing professional development
(CPD), audit and research. Each discipline should establish its
own rigorous framework, to ensure that patients' needs related
to their discipline are met. The CF Centre should have adequate
resources (e.g. staffing, IT equipment) and an infrastructure
(inpatient and outpatient facilities) that allow the MDT to
provide a level of care that is in accordance with the European
Cystic Fibrosis Society (ECFS) standards recommended in this
document, ensuring a safe, cost-effective and high-qualityservice. It is recognized that this may not be immediately
achievable throughout Europe, particularly in countries with a
low gross domestic product. It is crucial that where these
standards cannot be met, procedures are put in place to enable
them to do so within the short- to mid-term future, and that the
hospital management commits to supporting CF clinicians.
Without proper resources, a Centre is at risk of providing
uncoordinated and substandard care. A lack of homogeneity in
CF care will impact on patient outcomes [7].
At present, access to specialist CF services across Europe is
inconsistent. Qualifications, training and roles vary consider-
ably. Clinical practice should where possible be evidence
based and reflect current research findings, clinical guidelines
and consensus views. CF specialist professionals should be
appropriately trained, qualified and registered by the state/
national health authorities and legally recognized to practice
within that country. Specialists should practice within their
professional code of conduct and competency. They have a
responsibility to maintain, update and enhance their knowledge,
skills, efficacy and expertise through a proactive approach to
continuing professional development. Participation in uni- and
multi-professional audit and research, benchmarking, external
quality assessment schemes, service evaluation, development and
improvement, both of the specialist service and its provision as a
whole is essential. As a CF Centre may be the only facility in a
city or region, national and international programmes to support
CPD, benchmarking and service improvement are strongly
encouraged.
S6 S. Conway et al. / Journal of Cystic Fibrosis 13 (2014) S3–S22The following sections describe the ECFS recommended
standards for the individual specialties within the CF Centre.
2. Framework for the paediatric and adult Centres
Paediatric and adult CF Centres have many features in
common, so that the requirements outlined below usually apply
to both. As the health of children and adolescents continues to
improve, the emphasis in paediatric care is on the prevention of
disease progression. The morbidity and almost all of the mortality
associated with CF have shifted to adults. Adult services should
take into account the greater demands for inpatient provision and
the higher prevalence of multisystem complications. Even before
the transition from paediatric to adult care, it is most important
that the two Centres work closely together. Regular meetings
between the teams and shared protocols can smooth the transition
process for the young adult and minimize the changes to their
treatment. Effective communication between teams during this
period is crucial to the success of the transition process.
Children with CF will have their care transferred to adult
services around the time of their 17th/19th birthday. Children,
and their families, should understand that they will transfer to an
adult Centre at this age. The paediatrician is not trained or
experienced tomanage the emotional, social, or medical demands
of the adult patient. In the adult population, the manifestations of
this multisystem disease (e.g. CF-related diabetes, osteoporosis,
renal and liver complications and atypical infection) are
significantly more problematic. The adult physicians are also
best placed to fully inform patients about the potential risks of
pregnancy and are competent in the non-obstetric care of
pregnant women with CF.
The young person with CF and his/her family must be involved
in planning transfer at an early stage. The topic should be
introduced when the diagnosis of CF is made and reinforced at
appropriate intervals thereafter. Practical discussions should start at
around 11 years of age in the context of educational, social and
sexual conversations about growing up with a long-term condition.
There must be close liaison with an agreed protocol for transition,
and coordinators from both teams should be identified. The
adolescent and his/her carers should have the opportunity to
formally meet the adult team on more than one occasion. This is
optimally achieved by having joint clinics with the adult team
during the transition process. An opportunity to visit the adult
facilities should be made available to patients and parents. Written
information about each patient must be given to the adult team at
the time of handover.
2.1. The Centre
Many of the required features are the same for adult and
paediatric Centres. The CF Centre should have appropriate staff
and facilities to provide comprehensive care and be capable of
treating all CF-associated complications [4]. Patients should have
direct access to the Centre 24 h a day.
In order to justify and maintain an appropriate level of expertise
and experience, a specialist Centre should have a minimum of
100 adults or children with CF. In some circumstances, thegeographical location of a specialist CF Centre, or a low disease
frequency in certain populations, may mean that the number of
patients seen by a Centre is less, but never below 50. Centres with
fewer than 100 patients should be linked to a larger Centre until
there are sufficient patients, experience and resources to run an
independent service.
All patients with CF must have access to the Centre for
routine and emergency care and advice. Patients should be
reviewed regularly at a frequency appropriate to their individual
needs. Routine appointments for people with stable disease
should be every 2–3 months depending on the severity of their
disease. Newly diagnosed infants should be seen more
frequently (initially weekly).
All patients should have an annual assessment to ensure that, as
a minimum, a full medical, dietetic, physiotherapy and psychoso-
cial review is performed once a year and that all surveillance blood
tests are requested. The report should be written by a consultant
who should discuss the review findings with the patient/carers, and
the treatment plan should be agreed by all.
2.2. The multidisciplinary team
A core MDT of trained and experienced CF specialist
healthcare professionals should be responsible for patient care.
The MDT should be of appropriate size for the clinic population
and should include the following CF specialists and support staff:
• respiratory paediatrician/pulmonologist
• clinical microbiologist
• medical support from trainee(s)
• clinical nurse specialist
• specialist physiotherapist
• specialist dietitian
• clinical psychologist
• social worker
• pharmacist
• clinical geneticist
• secretarial support
• database coordinator.
There should be clear medical leadership of the MDT. The
roles and responsibilities of all senior doctors in the team
should be clearly defined.
The ECFS concurs with the staff numbers for paediatric and
adult Centres recommended by the UK CF Trust (Tables 1 and 2)
[6]. These numbers may vary according to health care organisa-
tion, geographical factors and local/regional variations in CF
services. For example, the numbers of physiotherapists may vary
according to the proportion of patients who self-administer
intravenous antibiotics at home. Staffing numbers should reflect
the model of shared care being used, taking into account time spent
by staff from the specialist Centre in assessing and treating patients
in a local hospital CF clinic. In addition, it is important that
adequate cover is available for annual leave, study leave, and
untoward events.
All members of the MDT must be registered with their
relevant national health profession's council/body, and be a
Table 1
Whole-time equivalents per clinic size: full-time paediatric patients a.
The MDT 50 patients 150 patients ≥250 patients b
Consultant 1 0.5 1 1
Consultant 2 0.3 0.5 1
Consultant 3 – – 0.5
Medical trainees 0.8 1.5 2
Specialist nurse 2 3 4
Physiotherapist 2 3 4
Dietitian 0.5 1 1.5
Clinical psychologist 0.5 1 1.5
Social worker 0.5 1 1
Pharmacist 0.5 1 1
Secretary 0.5 1 2
Database coordinator 0.4 0.8 1
a Patients with CFTR-related disorders should not be counted.
b When clinics care for significantly more than 250 patients, additional
consultants should be added to the multidisciplinary team (MDT) at a rate of
approximately one additional consultant per extra 100 patients. Additional
allied health professionals and support staff will also be required. There is likely
to be a limit to the number of patients who can be cared for effectively in a CF
Centre. This number will vary according to the facilities available in the hospital
housing the Centre and the capacity of that hospital to support adequate staffing
for the Centre. The MDT in individual Centres should review patient numbers
annually and appreciate when resources are becoming stretched beyond the
limit allowing care to be delivered to the standards recommended in guidelines.
Paediatric patient numbers are likely to remain relatively stable but adult
numbers are increasing every year. The need to establish a new adult Centre in
any region must be considered proactively. Supply must precede, or coincide
with, need.
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group. They must have specialist knowledge and be experi-
enced in the care of children and/or adults with CF. They must
maintain CPD through attendance at local study days and
national and international CF conferences.2.3. Access to other specialists
It is essential that there is access to other medical and
surgical specialists as needed. Essential supporting disciplinesTable 2
Whole-time equivalents per clinic size: full-time adult patients a.
The MDT 100 patients 150 patients ≥250 patients b
Consultant 1 0.5 1 1
Consultant 2 0.3 0.5 1
Consultant 3 – – 0.5
Staff grade/fellow 0.5 1 1
Specialist registrar 0.4 0.8 1
Specialist nurse 2 3 5
Physiotherapist 2 4 6
Dietitian 0.5 1 2
Clinical psychologist 0.5 1 2
Social worker 0.5 1 2
Pharmacist 0.5 1 1
Secretary 0.5 1 2
Database coordinator 0.4 0.8 1
a Patients with CFTR-related disorders should not be counted.
b See footnote in Table 1.and services include: gastroenterology and hepatology (with
expertise to perform emergency endoscopic ligation of oesoph-
ageal varices); diabetes and endocrinology; ear, nose and throat
surgery; cardiothoracic and general surgery; specialist anaesthe-
sia and pain control; rheumatology; nephrology; obstetrics and
gynaecology; psychiatry; intensive care; and interventional
radiology (with expertise to perform emergency bronchial arterial
embolization, and elective percutaneous ultrasound-directed
gastrostomy).2.4. Centre infrastructure
The facilities at the CF Centre must be appropriate for all age
groups. There should be sufficient capacity within the Centre for
outpatients to be seen urgently whether this is within a clinic
session, in a day-case unit or during a ward visit. The number of
inpatient beds should be sufficient to allow non-urgent patients to
be admitted within 7 days and urgent patients to be admitted
within 24 h. The hospital ward nursing staff who are in contact
with patients should have sufficient knowledge and experience of
CF care. Finally, there should be resources and staffing available
for home intravenous antibiotic administration supervised by
trained outreach nurses.2.5. Segregation
All CF Centres must have a clear policy for infection
prevention and control, and facilities must allow for adequate
patient segregation to prevent cross-infection. Patients should not
share rooms, bathrooms or toilets during a hospital stay and
should not be in contact with each other in waiting areas, such as
in CF clinics, wards, the pharmacy and radiology departments.2.6. Access to specialist investigations
Within the specialists CF Centre, there should be easy access
to specialist investigations. These include biochemistry and
haematology laboratories for routine tests as well as analysis of
sweat and measurement of fat-soluble vitamin levels, aminogly-
coside levels, and measures of glucose metabolism (including
continuous glucose monitoring systems). The microbiology
services should have the ability to process samples from people
with CF and to reliably detect Burkholderia spp., non-tuberculous
mycobacteria, and fungal infection. Molecular pathogen typing
and immunology for allergic bronchopulmonary aspergillosis
monitoring should also be available.
Physiology must include lung function measures (both ward
and outpatient spirometry), pulse oximetry including overnight
O2/CO2 monitoring, exercise testing and fitness-to-fly testing.
The radiology and nuclear medicine service should include
computed tomography (CT) scanning, liver ultrasound, and
dual energy X-ray absorptiometry (DXA scan) bone scanning.
High-frequency pure tone audiometry and flexible bronchos-
copy should also be available.
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Facilities must exist for a parent/carer to stay with their child
in hospital, and for a child to receive suitable education within
the hospital if they cannot attend school due to illness. Related
to these facilities should be access to appropriate play and/or
recreation, with facilities for study.
The CF Centre should be committed to active participation in
clinical and translational research, and encourage patient partici-
pation in clinical trials. Each Centre should aim to be part of the
expanding European Clinical Trials Network (www.ecfs.eu/ctn).
2.8. European policy aspects of CF Centre care
CF is a rare disease (i.e. b1 in 2000), and as such belongs to
the domain of several European Union (EU) policy initiatives
relevant to research and healthcare. CF Centres, in compliance
with the European Committee of Rare Disease Experts guidelines
for Centres of Expertise for rare diseases, could operate within the
frame of the newly established European Reference networks for
rare diseases. As a rare disease, CF has a special status (Art. 54) in
the Cross-Border Directive that facilitates exchange of expertise
and eventually patients, and could thus address disparities in care.
The development of CF Centre care in EU member states is
supported by the EU Council Recommendation on action in the
field of rare diseases (EC 2009/C 151/02). The introduction of
orphan medical products into CF care also falls into such policy
initiatives.
3. Framework for the specialist doctor
3.1. The CF consultant
The Consultant who works in a specialist CF Centre should
have received accredited training in paediatric or adult CF care,
usually within the context of respiratory specialization. The
knowledge and skills that the CF Consultant should have
acquired are detailed below [8].
3.1.1. Knowledge
The CF Consultant should have knowledge of the epidemiol-
ogy and pathophysiology of CF and the aetiology of respiratory
and non-respiratory manifestations and complications of CF,
including massive haemoptysis, pneumothorax, respiratory fail-
ure, gastrointestinal disease, diabetes, problems of fertility and
pregnancy (adult care) and psychosocial problems. The relevant
investigations required, including microbiological investigations,
non-invasive imagingmodalities such as chest X-ray, CT imaging
scans, should be familiar to the Consultant. The CF Consultant
also needs to be familiar with the pharmacology of inhaled, oral
and systemic drugs that are prescribed to patients and with the
varied interventions employed by physiotherapists. The nutrition-
al requirements of individual patients should be monitored and
enteral tube feeding initiated when appropriate.
Finally, the CF Consultant should know the indications for
lung transplantation and be experienced in discussing this option
with patients and carers.3.1.2. Skills
CF Consultants should be able to apply the above knowledge
to the management of respiratory and non-respiratory manifes-
tations and complications. They should also be able to interpret
the results from sputum microbiology tests and evaluate the
functional status of patients. CF Consultants should also have
good communication skills so that they can educate their patients
and carers as the disease evolves.
The CF Consultant's job plan should include adequate time
allocation for CF patients, both for clinical tasks as well as
managerial duties. This must include the capacity to maintain
his/her own CPD in CF, which should involve attendance at
national or international respiratory/CF meetings. In order to
keep up to date with advances in treatment and research, the CF
Consultant should spend a minimum of 50% of his/her working
time dedicated to CF issues.
3.2. The clinical lead
The Director of the specialist CF Centre is usually the Clinical
Lead and will be expected to lead the CFMDT. He/she should act
as a link between clinical experts and the hospital management.
The Clinical Lead/Centre Director will be expected to head the
team and to ensure that: the needs of its members are met in terms
of professional development and adequate support; that oppor-
tunities for attendance at national and international CF meetings
are available; and that research is encouraged. The Director
should also ensure that a team approach is maintained and that all
members of the CF MDT have the opportunity to have their
observations and opinions considered in patient management.
It is essential that the Director understands the financial
framework underpinning the country's healthcare system in
order to develop and protect the financial support needed for
the CF service. The Director should lead on staff recruitment,
aiming to realize the human resource numbers as recommended
in these Standards of Care. He/she should ensure that CF MDT
meetings are held weekly, that Centre outcome measures are
audited and that the results are reported back to the team so that
standards of care are improved. In order to achieve the latter,
the Director needs to oversee accurate data collection and
documentation and that transfer of these data to the national and
European registries is carried out.
In some Centres there may be co-leads/directors of the
service. Clear definition of responsibility and communication is
essential in this situation.
4. Framework for specialist nursing care
4.1. The role of the CF Clinical Nurse Specialist
The role of the CF Clinical Nurse Specialist should include
[6]:
• education, advocacy and psychosocial support, particularly
at important times such as:
○ notification of a screening result and diagnosis
○ first admission to hospital
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○ a second diagnosis (e.g. CF-related diabetes)
○ transition from paediatric to adult care
○ reproductive issues, pre- and postnatal care
○ transplant and end-of-life issues
• provision of support and education at home, particularly for
home intravenous antibiotic therapy, nebulizer therapy,
enteral feeding and non-invasive ventilation
• provision of education to others about CF, including nurseries,
schools, places of higher education and work places
• acting as a link between the patient and family, primary care,
community services and hospital
• acting as a resource for training and education of other
professionals involved in CF care.
4.2. Access, availability and facilities
There should be an adequate number of Clinical Nurse
Specialists with expert knowledge of CF in the MDT [9]. The
CF Clinical Nurse Specialist should deliver skilled support,
advice and care directly to the patient and family wherever it is
needed, both when attending hospital and at home. The service
will vary according to differing patient populations, their needs
and requirements. The role of the CF Clinical Nurse Specialist
should continuously develop to meet the needs of the local CF
population [4].
CF Clinical Nurse Specialists need sufficient time, office
space, computer/printer and financial support in order to be able
to provide a reliable service. They should stay in regular contact
with patients and families in between clinic visits and therefore
need access to technology such as email, phone and SMS texting.
4.3. Key stages for delivery of care
4.3.1. Diagnosis
Diagnosis through newborn screening is now common in
many countries. The CF Clinical Nurse Specialist plays an
active role in talking to parents at diagnosis and providing
ongoing support and continuing education following the initial
discussion. Where screening is not available, the CF Clinical
Nurse Specialist plays a similar role offering support, advice
and education, which has to be individualized at a level and
frequency to meet differing needs, whether diagnosis is within
the first year of life, in older children or during adulthood.
Contact between the CF Clinical Nurse Specialist and the
patient/parent is therefore essential, whether this is in hospital,
through home visiting, or via email or telephone.
4.3.2. Pre-school
For many, after coming to terms with the diagnosis and
learning how to carry out treatment regimens while adjusting
back to family life, the early years can seem almost normal.
However, there are a few areas where the CF Clinical Nurse
Specialist can provide education, practical advice and psychoso-
cial support [10], such as: administering medication; nutrition;
adjusting pancreatic enzyme replacement therapy (judging the
correct amount or offering advice when the child refuses to takethe enzymes) in conjunction with the CF Dietitian; recognizing
chest infections and making decisions about when to ask for
advice or to start treatment; managing airway clearance and
exercise in conjunction with the CF Physiotherapist; starting
nursery; dealing with siblings; planning further children.
4.3.3. School age
When a child starts school it can be a traumatic experience
for any parent. When the child has CF, parental anxiety about
loss of control is likely. Many CF Clinical Nurse Specialists
will visit the school (with parental permission) to educate and
prepare teachers for managing CF in areas such as: maintaining
good nutrition at school; administration of pancreatic enzymes
and other medication (e.g. nebulizers/inhalers/oral); liaising
with the school nurse; facilitating time off for hospital visits/
admissions; dealing with the child's growing independence;
advising on issues surrounding non-adherence, especially
eating and airway clearance. The CF Clinical Nurse Specialist
can help parents at this time, particularly with outreach contact
as it gives parents time away from the clinical setting and
allows them to discuss their anxieties in a safe and familiar
environment.
Most school-age children with CF are relatively well and take
part in all academic, sporting and social activities provided by the
school. Occasionally, extra treatment is necessary. Supporting
treatments such as intravenous therapy or enteral feeding in the
home often allows children to continue attending school. The
provision of an outreach service can help, as routine checks
(such as spirometry) can be performed by the CF Clinical Nurse
Specialist, and problems can be identified early [11,12].
4.3.4. Adolescence
Adolescents with CF go through the same physical and
emotional changes and have the same expectations as their
healthy peers, irrespective of the severity of lung disease [13].
The CF Clinical Nurse Specialist should be able to have open
and honest discussions about issues such as: recreational drug
use and the effects on CF; sexuality, safe sex and contraception;
fertility and pregnancy; further education and employment;
body image and self-esteem; adherence to treatment regimens;
relationships with parents; promotion of self-care, adherence
and responsibility; accurate information about their disease and
treatment.
CF Clinical Nurse Specialists need to be sensitive and
honest when giving information to young people with CF
[14–16]. Much of the information they (and their families)
receive is from peers, the media and the Internet. Information
given by the CF Clinical Nurse Specialist must therefore be
correct and up to date.
4.3.5. Transition from paediatric to adult care
All children with CF should move from paediatric to adult
care. The importance of getting this transition process right is
widely recognized [17,18]. Transition from paediatric to adult
care happens at a time when the young person with CF is
moving into adulthood in other areas of their life, such as
further education or employment, forming relationships and
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can therefore be difficult for many reasons. CF Clinical Nurse
Specialists involved with the transition process need to be
aware of the many barriers that can prevent this process being
successful [19,20]. Both the paediatric and adult CF Clinical
Nurse Specialists play an important role in ensuring a
successful transition and will manage details such as: patient
and parent involvement in decision making; clear communica-
tion between paediatric and adult CF MDTs; appropriate
transition clinics involving the MDT; ensuring attendance at the
adult clinic with appropriate follow-up.
Young people may find that their first admission to the adult
Centre is to an unfamiliar ward where they do not know the staff.
For these individuals and their families, the first inpatient
admission requires an increase in awareness and sensitivity
from the ward staff and further CF Clinical Nurse Specialist
support to both the patient and the family. The CF Clinical Nurse
Specialist should liaise between the ward and the CF MDT.
4.4. Adult issues
CF Clinical Nurse Specialists play a vital role in helping
adults maintain a balance between adhering to treatment
and their lifestyle, and recognize the need to help individuals
adapt treatment regimens to suit them. This will include:
educating employers and work colleagues; liaison with govern-
ment agencies and the work place to ensure maximum support
(financial and practical) to enable patients to stay employed or to
re-train; advocacy on a patient's behalf with local social services;
educating and liaising with family doctors and local pharmacists;
negotiating easier access to classes at school or university;
increasingly, CF Clinical Nurse Specialists will work in
collaboration with the family doctor, social services and the CF
team to support patients caring for their ageing parents; providing
education, counselling and support around reproductive issues
for both men and women with CF; practical and emotional
support throughout the neonatal and postnatal periods.
Complications occur more commonly in older patients with
CF [21–23]. An outreach service led by a CF Clinical Nurse
Specialist may have to manage complex medication regimens
and organise care to help maintain a lifestyle/treatment balance.
4.5. Transplantation and end-of-life issues
When admissions become more frequent, longer in duration
and the burden of treatment increases, patients or their families may
wish to raise the issue of lung transplantation. Early discussion
with the team raises questions and concerns for both patients and
their families. The CF Clinical Nurse Specialist's role as advocate
and educator for the patient is vital in this decision process.
CF continues to be life limiting. Death in childhood, although
uncommon, does occur. Unlike other chronic diseases, the end
stages of CF can be difficult to recognize. Patients often need
opportunities to discuss their fears and anxieties but may feel
uncomfortable or protective talking about these issues with their
family for fear of upsetting them or ‘letting them down’.
Advocacy allows the CF Clinical Nurse Specialist to facilitatediscussion between the patient and family. Early discussion
about an individual's wishes for the terminal stage of their disease
is essential to aid appropriate care planning. Issues that may
be raised include transplantation, wills, funeral arrangements,
writing letters or diaries to the family and where they would like
to be when they die [24,25].
The CF Clinical Nurse Specialist plays a key role in
providing individual emotional support for parents/partners.
Although some families are willing to return to the hospital,
many find this difficult. Visiting the family at home allows
bereavement support to be offered in a safe and comfortable
environment. Home visiting also allows other family members,
siblings or grandparents for example, to receive support.
4.6. Core competencies, qualifications and professional
development
4.6.1. Core competencies
The CF Clinical Nurse Specialist should be competent in the
following key areas.
• Clinical practice
• Diagnostic and assessment skills
• Treatment skills
• Recognizing and monitoring change
• Facilitating programmes of care
• Clinical research and audit
• Education
• Knowledge of CF and associated issues
• Evidence-based practice
• Teaching and training: patients, carers, other healthcare
professionals
• Communication
• Patients and carers
• MDTs
• Liaison with clinical, social, educational, employment and
other lay agencies
• Support and advocacy
• Social care
• Advocacy
• Counselling skills
• Legal and ethical issues.
4.6.2. Qualifications and professional development
The CF Clinical Nurse Specialists must be registered as
licensed practitioners in their country. They should also have
specialist knowledge and be experienced in the care of children
(including specific paediatric training) and/or adults with CF.
The CF Clinical Nurse Specialist must contribute to research in
all areas of CF, either through developing individual projects or
participating in research carried out by the CF MDT, and
maintain CPD through attendance at courses and conferences.
CF is a demanding disease to manage for the patient, family
and the CF MDT. The CF Clinical Nurse Specialist must act as
a link between the patient and family, primary and community
services, and the hospital. The CF Clinical Nurse Specialist has
a responsibility to ensure that every patient receives appropriate
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support and good-quality treatment through the coordination of
care between patient and family, community services and
hospital, both practically and through support and advice.
5. Framework for physiotherapy care
The specialist CF Physiotherapist should take the lead in
providing high-quality treatment of airway clearance, physical
exercise and inhalation therapy. Physiotherapy programmes in
CF care are primarily preventive, and regular input is required
from the time of diagnosis. The aims of therapy are to maintain
ventilation in all parts of the lungs, to postpone progression of
pulmonary disease, to stimulate establishment and retention of
normal physical capacity and to avoid pain and musculoskeletal
complications due to pulmonary or bone disease [26]. The CF
Physiotherapist should also develop strategies for the manage-
ment of complications or co-morbidities experienced by the
ageing patient and should optimize the respiratory physiother-
apy programme, which includes highly technical equipment,
non-invasive ventilation and physical exercise with oxygen
supplementation. Physical rehabilitation is essential for patients
on a transplant waiting list.
5.1. The role of the CF physiotherapist
The CF Physiotherapist should be available for regular contact
and assessment of the patient for treatment, lung function testing,
physical surveillance and therapy evaluation. The frequency of
this will vary according to the patient's age and clinical status but
as a minimum should happen at every routine outpatient clinic
and daily during each hospitalization (including when patients
are admitted under the care of other specialists and to intensive
care). A more extensive assessment should take place annually.
5.2. Regular assessment and therapy
Regular lung assessments by the CF Physiotherapist should
include lung function test data, respiratory signs, degree of
dyspnoea, oxygenation cough characteristics and questioning
about activity of everyday life. All interventions should be
tailored to the individual, with consideration of their age, severity
of disease, physical side-effects or complications, and social and
domestic circumstances.
5.2.1. Inhalation therapy
As the CF Physiotherapists are responsible for inhalation
therapy they should be familiar with techniques, equipment
provision and appropriate maintenance of devices. There is a
need for consideration of timing of inhalations in relation to
airway clearance as there may be a positive interdependence
between the two. Education of patients in appropriate inhalation
techniques is essential for optimal deposition of inhaled drugs.
The CF Physiotherapist should be familiar with the appropriate
nebulizer systems proven to be safe and effective in the delivery
of the medications prescribed. Cleaning and maintenance of thewhole nebulizer system are essential to ensure that medications
are delivered optimally and safely [26,27].5.2.2. Airway clearance therapy
Physiotherapists are responsible for airway clearance
therapy. This involves knowledge and experience of the full
range of techniques available and immediate evaluation of
therapy, for example by expiratory sounds, sputum volume and
characteristics and by ability to control cough. Alternative
physiotherapy techniques should be recognized and considered
for individual patients. There are a variety of effective airway
clearance techniques that allow patient independence. These are
based on sound physiological concepts and allow the CF
Physiotherapist to individualize treatment programmes [28].
There is no standard airway clearance regimen or conclusive
evidence to promote one technique over another [6,26,29–37].5.2.3. Postural and musculoskeletal assessment
Assessment of postural and musculoskeletal function is
carried out to evaluate therapy. Physical exercises aimed at the
maintenance of good posture and chest mobility should be
included in the treatment from the beginning. As with all
physiotherapy interventions the exercises should be individu-
ally tailored to each patient [26,38,39].5.2.4. Exercise capacity
Exercise capacity and the opportunities for exercise pre-
scription for the person with CF include any pre-transplantation
preparation. Reduction in exercise capacity is associated with a
decline in respiratory function and survival [40,41]. Physical
exercise has been reported to improve lung function and
decrease habitual inactivity in children with CF [42]. The CF
Physiotherapist should perform regular exercise testing with
a frequency dictated by disease progression, and in cases of
specific needs like transplantation assessment or evaluation of a
treatment. Care should be taken when prescribing exercise
activities for patients with advanced disease, particularly when
they may also experience haemoptysis, exercise-induced
desaturation requiring supplementary oxygenation, pulmonary
hypertension, cor pulmonale, joint arthropathies and other
co-morbidities [26]. The CF Physiotherapist should also assess
supplementary oxygen needs, for exercise or ambulation [26,43].5.2.5. Non-invasive ventilation
It is recognized that non-invasive ventilation is a useful
therapeutic adjunct to support airway clearance therapy and
reduce the work of breathing and fatigue experienced by the
severely ill patients during treatment. Non-invasive ventilation
may also be useful during exercise management to decrease
breathlessness, improve oxygenation and, consequently, to
maintain or improve exercise tolerance [44–46]. Additionally,
non-invasive ventilation is implemented to facilitate optimal
function in patients with end-stage disease and possibly as a
bridge to transplantation [45].
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Surveillance regarding the incidence of urinary and faecal
incontinence should also be the responsibility of the CF
Physiotherapist. A sensitive and open approach with early
recognition of symptoms should be adopted; questioning can
occur as early as 10 years of age [47,48].
The CF Physiotherapist should also be responsible for:
• management of associated complications and issues with
adherence while continuing to promote independence that is
age appropriate
• appropriate inhalation and airway clearance therapy and
physical exercise programmes during pregnancy [49]
• ensuring the appropriate maintenance and function of
equipment provided for therapy and nebulization
• the education of patients, carers, teachers and local physio-
therapists; the physiotherapists should work closely with the
other professionals for the benefit of the patients' holistic care
• palliative care, especially in relation to relieving dyspnoea
in the terminally ill, and advising on when to withdraw
non-invasive ventilation.
5.3. Service provision
When patients are resident in hospital for the treatment of an
exacerbation or for routine management they should be
reviewed by the CF Physiotherapist within 24 h of admission,
and a treatment plan focusing on airway clearance, inhalation
therapy and exercise tolerance should be implemented. The
CF Physiotherapist should have a comprehensive knowledge
of all techniques, respiratory pathophysiology, the rationale
for alternative approaches and any associated contraindications
to the treatment techniques available [28]. CF physiotherapy
services should be available 7 days a week, with an out-of-
hours physiotherapy service available for those patients who
may deteriorate overnight.
5.4. Professional development, research and availability
Education, clinical audit, research and contribution to a CF
registry should be pursued. CPD is integral to the work of the
CF Physiotherapist who should maintain and increase specialist
knowledge by attendance at relevant postgraduate courses,
lectures, and national and international conferences. They
should preferably be an active member of their national CF
physiotherapy group and be available to represent physiother-
apy interests for their country at meetings of the International
Physiotherapy Group for CF (IPG/CF) [50]. The CF Physio-
therapist should contribute to research, development and
evaluation by performing audits, participating in multicentre
studies and contributing data to registries. They should collect
annual data in order to evaluate their care [50,51].
6. Framework for dietetic care
A normal nutritional status is positively associated with
better lung function [52,53]. Healthy body weight, height andBMI are positively associated with survival [53–55]. Ensuring
normal growth in children and adolescents and maintaining a
normal BMI in adults is essential.
Specialist CF Dietitians have an integral role to play in
patient management and have overall responsibility for the
delivery of expert nutritional care. They should be actively
involved in the nutritional training, education, development and
support of other healthcare professionals involved in CF care.
Dietetic intervention should be both proactive and reactive,
evolving in response to the needs of each individual patient. It
is essential that the specialist CF Dietitian has expertise in
managing the complex nutritional challenges and rare compli-
cations of the disease.
6.1. The role of the specialist CF dietitian
The specialist CF Dietitian should take the lead in providing
high-quality treatment and care to ensure optimal nutritional
status, including nutritional screening and surveillance, and
regular patient assessment with review of all aspects of nutrition
and gastrointestinal status. The frequency and type of assessment
will vary with age and clinical status.
The specialist CF Dietitian should advise and educate patients
and carers about the principles of nutritional management in CF to
enable them to meet their nutritional needs and achieve optimal
growth, weight and body composition. Advice may be required
on the management of pancreatic insufficiency, fat-soluble
vitamin deficiency, altered gastric motility, gastro-oesophageal
reflux, impaired glucose tolerance/diabetes, reduced bone mineral
density, renal disease and liver disease.
Age-specific individualized advice should be offered. This
advice should consider psychosocial barriers (especially during
adolescence) and be supported by written literature, visual,
audio and/or audiovisual aids, computerized learning packages
and ‘apps’. This is an ongoing and evolving process and must
take into account the key times that may require more intensive
dietetic intervention and support, such as diagnosis, early
infancy, initiation of pancreatic enzyme replacement therapy,
weaning, adolescence and self-management, pregnancy, initi-
ation of enteral tube feeding, diagnosis of CF-related diabetes,
transplantation and end-of-life care.
It is important to remember that patients diagnosed later in life
tend to present atypically and have unique educational require-
ments. Improving adherence to the many prescribed nutritional
therapies is a key challenge. The specialist CF Dietitian should
provide a collaborative approach to increasemotivation to change
and support patients' efforts to change. This is based on providing
information and facilitating open discussion. It is important to
address emotional and perceptual barriers to adherence, e.g. a
reluctance for females to gain weight during adolescence.
6.2. Clinical governance, research and quality framework
The specialist CF Dietitian should be a member of, and an
active participant in, specialist interest groups locally, nationally
and internationally, (e.g. European Cystic Fibrosis Nutrition
Group) in order to support their practice. They should be
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6.3. Dietary assessment
6.3.1. The annual assessment
Dietetic staffing should allow for a structured annual
assessment of dietary intake and nutrition. Formal assessment of
dietary intake using a written diet and enzyme diary should be
targeted at selected individuals only; in large CF Centres, such an
exercise is unsustainable if applied to all patients and is unlikely to
provide additional information for patients with stable nutritional
status. The annual evaluation should address all aspects of
nutritional status assessment, nutritional intake, pancreatic enzyme
replacement therapy, and the management of nutritional and
metabolic complications. The annual assessment will help to
provide the framework for future care planning and anticipatory
guidance.
The reader is referred to the document “European Cystic
Fibrosis Society Standards of Care: Best Practice guidelines –
Optimal Nutrition and Management of Metabolic Complications
of Cystic Fibrosis” for details on the assessment of the following:
• pancreatic status and absorption
• growth and nutritional status
• bone mineral density, and
• glycaemic status.
6.4. Service provision framework
Traditionally the framework for service provision is divided
into:
• inpatient care
• outpatient care
• home care
• shared care
• transitional care
• annual review.
All patients should have access to a specialist CF Dietitian at
all of these times. The same dietitians should provide inpatient
and outpatient advice to ensure continuity of care and to
prevent the important minutiae of care being overlooked.
Advances in telecommunications and technology allow oppor-
tunities to re-evaluate service delivery.
6.5. Key considerations of service provision
6.5.1. Inpatients
A clear discharge plan and follow-up arrangements should
be provided for patients treated in hospital, especially for those
requiring ongoing nutritional support.
6.5.2. Home treatment
For those being treated with intravenous antibiotic therapy at
home, there should be access to a specialist CF Dietitian at thestart and end of this treatment, with ongoing nutritional support
provided remotely (e.g. by telephone, telemedicine) or via the
CF Clinical Nurse Specialist. There should be clear channels of
communication between the CF Clinical Nurse Specialist and
the specialist CF Dietitian.
6.5.3. Outpatients with CF-related diabetes
Outpatients with CF-related diabetes should have access to a
specialist CF Dietitian with experience in the management of
this CF complication.
6.5.4. Shared care
In general, due to the complexity of the dietetic needs of adults
with CF, shared care is not appropriate. In paediatric Centres
there should be:
• protocols for the delivery of care and lines of responsibility
for nutritional management
• an identified dietitian within the shared care hospital who
will liaise with the specialist CF Dietitian at the Centre
• review of all patients by the Centre's specialist CF Dietitian
at least twice a year.
6.5.5. Transition
The paediatric and adult specialist CF Dietitians should
work together to promote autonomy, facilitate self-management
and ensure a smooth transition. At the time of transfer, the
paediatric specialist CF Dietitian should provide a clear and
concise summary of the nutritional management and challenges
for each patient. Where possible the paediatric specialist CF
Dietitian should provide a written treatment plan.
7. Framework for microbiology
A Clinical Microbiologist with specialist knowledge of CF
infection should be part of the CF MDT. This individual may be
a medically trained clinical microbiologist/infectious disease
specialist; alternatively, a clinical scientist with relevant knowl-
edge and experience may be able to undertake this role. The CF
Clinical Microbiologist should work closely with the microbiol-
ogy laboratory providing diagnostic services for the CFMDT and
also with the local infection control and prevention team.
In order to provide support to the CF MDT for the diagnosis
and treatment of infection, the CF Clinical Microbiologist
needs to know about the range of infections in CF. In particular,
they need to be aware of the role of unusual micro-organisms,
the risk of cross infection and the impact of long-term chronic
infection on microbiological laboratory testing and treatment.
In addition to a good basic knowledge, the CF Clinical
Microbiologist should have evidence of CPD in CF microbi-
ology and attend specialist CF meetings and conferences.
7.1. The role of the CF Clinical Microbiologist
The CF Clinical Microbiologist should ensure that appropriate
laboratory microbiology provision is in place. The individual
may be part of the management of the laboratory. Alternatively,
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which case the CF Clinical Microbiologist should be involved
with setting the terms of the contract and act as an advocate for
the CF Centre.
The CF Clinical Microbiologist should advise on the
diagnosis and treatment of infection including the monitoring
of antibiotics. This may be achieved by attendance at the CF
MDT meetings. The CF Clinical Microbiologist should also act
as an advisor on infection prevention and control in the CF
Centre. This may be delegated to the designated infection
control doctor if such a position exists.
7.2. Overview of laboratory services
The CF Clinical Microbiologist should ensure that the full
range of microbiology laboratory tests needed for the CF
Centre is available and that the laboratory service provided is
based on published guidelines [56–58]. The laboratory should
be fully accredited by a recognized national scheme for clinical
microbiology and should participate in external quality
assurance, which includes CF-associated pathogens. There
should be provision to send relevant samples to a reference
laboratory specializing in CF microbiology when required.
The laboratory should provide accurate and timely results to
the CF Centre with an agreed system for notifying urgent and
important results. The technical staff in the laboratory should
have sufficient expertise and knowledge to deal with the
complex microbiology of CF infections.
There should be a framework for recording and investigating
errors and other incidents, with evidence of how the lessons
learned are used to inform a programme of service improvement.
The service should be regularly audited. Examples of audits
are the turn-around time (i.e. the time between the receipt of the
sample in the laboratory and the time when the result is
available to the CF MDT), the accuracy of identification and
susceptibility testing, and the appropriate and prompt commu-
nication of urgent results to the CF MDT.
7.3. Clinical microbiology services and the CF MDT
The following items should be agreed between the CF MDT
and the clinical microbiology service.• Which respiratory samples should be taken and how should
they be processed (e.g. sputum, bronchoalveolar lavage,
cough swab or a pharyngeal swab).
• Which samples should be taken for the diagnosis of an
infected intravascular line.
• Diagnosis of other infections including infections of the gut
(e.g. enteric viruses, when and how to test for toxigenic
Clostridium difficile)
• The level of identification of micro-organisms (e.g. genus,
species, subtype) required in individual cases. This may
include a discussion on the tests that can be performed in a
local laboratory and what may need to be referred to a
specialist laboratory with more advanced testing methodology(e.g. confirmation of first infection with Burkholderia spp.
with accurate species identification).
• Typing methods and frequency of typing (i.e. how often the
CF MDT should send samples for routine surveillance and
when additional typing should be done due to suspicion of
cross infection)
• Measurement of antipseudomonal antibodies where
appropriate
• Provision of diagnostic testing for fungal and mycobacterial
infection together with level of identification and role of
typing
• Susceptibility testing — agreement on the antibiotics to be
tested and when susceptibility testing is helpful
• Virology services should include rapid identification of highly
pathogenic viruses that may spread between patients — both
familiar (e.g. influenza virus) and emerging viral pathogens
(e.g. SARS, MERS coronavirus).
• Which results need to be phoned urgently to the CF MDT
(e.g. first growth of Pseudomonas aeruginosa, new isolation
of Burkholderia cepacia complex and other Burkholderia
species, MRSA, possible Mycobacteria seen in sputum).
• Advice on infection prevention and control.
In addition, a robust framework for communication between
the microbiology services and the CF MDT should be agreed
(e.g. telephone contact, ward rounds to review patients,
participation in MDT meetings).
7.4. Clinical advice on treatment of infection
The CF Clinical Microbiologists should work with the CF
MDT to draw up guidelines for the use of antimicrobials, including
the selection of treatment for clearance of new infections, therapy
for acute exacerbation and long-term suppressive antibiotics.
The aim is to reduce morbidity and hospital admissions and to
use antibiotics responsibly in order to limit the development of
resistance.
There must be provision of therapeutic drug monitoring of
antibiotics. The CF Clinical Microbiologist should ensure that
guidelines and advice are available on the maintenance of
optimum antibiotic levels in the patient in order to promote
effective treatment while minimizing side-effects.
7.5. Infection prevention and control
The CF Clinical Microbiologist should work with the CF
MDT and the local infection control team to develop a local
infection control and prevention policy and procedures in line
with expert national and international guidelines [59–63]. This
policy should include:• how patients with transmissible infections are managed,
both in the community and in hospital, in order to prevent
the spread of infection
• surveillance for transmissible infection (e.g. how often to
screen and which samples to send to the laboratory)
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transmissible micro-organisms
• guidelines for staff with infections
• the investigation of outbreaks
• the provision of facilities for the CF Centre and the
outpatient department — this should include the cleaning
and maintenance of equipment and involvement in any plans
for refurbishment or re-build of the department.
7.6. Role in clinical research and data collection
CF Clinical Microbiologists can have an active role in CF
clinical research. They may be involved with the design of
innovative research but also have a role in the provision of
reliable and accurate laboratory support for clinical studies. They
can also help to ensure that accurate microbiological results are
available for national and international database collection.
8. Framework for medicines management
Optimal care of people with CF requires complex multidrug
treatment plans. These drugs may be administered by oral,
intravenous and inhaled routes. Adverse effects and drug
interactions are common.
Many of the drugs are expensive and require specialist
assessment and instruction on optimal administration. Adherence
is a major challenge for patients and parents/carers. Non-adherence
is associated with poor outcomes. CF Centres must have an
effective medicines management programme to support patients in
optimizing their therapy. The CF Clinical Pharmacist is pivotal in
this process [64]. In European countries, decentralized clinical
services, with a pharmacist working in the ward at least 50% of
his/her time, or with pharmacists visiting wards daily, are not
very common [65]. Only two countries, UK and Ireland, have
developed these clinical services to a significant extent [65].
8.1. The role of the CF Clinical Pharmacist
CF Clinical Pharmacists have a central role in managing
medicines effectively [66]. The overall goal of clinical pharmacy
activities is to promote the correct and appropriate use of
medicinal products and devices [67]. These activities aim to:
• maximize the clinical effect of medicines (i.e. using the most
effective treatment for each patient)
• minimize the risk of treatment-induced adverse events
(i.e. monitoring the therapy course and the patient's
compliance with therapy)
• optimize the expenditures for pharmacological treatments
borne by the national healthcare systems and by the patients.
The principle objective of the service provided by the CF
Clinical Pharmacist is to provide patient-focused pharmaceuti-
cal care, defined as the responsible provision of medication
to achieve definite outcomes that improve patients' quality
of life and long-term survival. The service is the process
through which the pharmacist cooperates with a patient andother healthcare professional in designing, implementing and
monitoring a therapeutic plan to produce these specific health
outcomes [68].
Effective provision of a clinical pharmacy service to the CF
Centre relies on the knowledge and skills of a CF Clinical
Pharmacist and the quality of various support services, such as a
medicine information service with experience in the problems of
CF and paediatrics (if applicable), and the necessary procurement
and distribution services that can provide an efficient medicine
supply service for inpatients. A dispensing service should also be
provided as required. Access to an on-call service for the supply
of urgent medication, information and advice for inpatient
care, and an aseptic dispensing service for the preparation of
intravenous antibiotics including complex desensitization regi-
mens should also be available.
The CF Clinical Pharmacist should:• dispense medications to inpatients or outpatients as required
in their institution
• attend CF wards rounds and CF MDT meetings
• support and provide information to other pharmacists in the
department who may not be familiar with CF
• liaise with paediatric and adult Centres during transition of
care and transfer of patients
• support and provide information to pharmacists working in
primary care and other hospitals
• maintain CPD through appropriate study and attendance
at relevant study days, and at national and international
conferences
• network with other CF Pharmacists for advice and CPD.8.2. Pharmaceutical care practice for CF Clinical Pharmacists
8.2.1. Managing formularies, clinical guidelines and treatment
protocols
The CF Clinical Pharmacist should assist in the completion of
formulary applications to ensure that the appropriate medicines
are introduced into clinical practice. They should also assist in the
development and support of homecare services, such as home
intravenous antibiotics, and manage and monitor the delivery of
medication in this setting.
Effective communication should exist between the CF
Clinical Pharmacist and other members of the CF MDT. As for
all clinical professionals in the CF MDT, the Clinical Pharmacist
should participate in CPD and attend CF conferences and relevant
study days. They should also contribute to education and training
of other healthcare professionals, including those working
in primary care, as appropriate. The CF Clinical Pharmacist
should act as an advisor on the legal and ethical responsibilities of
using medicines, including sourcing and administration of
unlicensed and off-label medicines. Any problems with medica-
tion supply should be resolved by the CF Clinical Pharmacist and
communicated to the CF MDT.
The CF Clinical Pharmacist may be required to collaborate
with CF research and development and assist in the completion
of individual funding requests or exceptional case requests for
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no such mechanism exists to currently fund that treatment.
8.2.2. Medication reconciliation/history taking
The CF Clinical Pharmacists is responsible for medicines
reconciliation at admission/transfer from other institutions and on
discharge, including alternative over-the-counter medications,
trial medications and medications used for other conditions. They
should ensure that an accurate history is recorded, including
previous allergic reactions/adverse drug reactions.
8.2.3. Prescription monitoring and medication review service
In the monitoring and review of patient medication, the CF
Clinical Pharmacists should ensure that medication and the
formulation are appropriate for the patient, oversee extended
prescribing for allied healthcare professionals including other
pharmacists, and check for drug interactions. The CF Clinical
Pharmacist is also responsible for ensuring that prescriptions are
complete, unambiguous and legal, and for detecting potential
medication errors.
8.2.4. Identifying patient and medication risk factors
It is the CF Clinical Pharmacist's responsibility to ensure that
patient characteristics, including age, pregnancy or breast feeding,
and organ dysfunction are taken into account when medicines are
prescribed, and to check the response to previous and current
medication. The use of non-drug and complementary therapies
should also be taken into account when managing the patient's
medication.
8.2.5. Preventing, detecting and reporting adverse drug reactions
The CF Clinical Pharmacist needs to document and report
all reactions to newer medications and serious reactions to
established medications to the appropriate national body. This
includes documentation of individual toxicity/allergies/hyper-
sensitivity reactions and contraindications, and monitoring for
any adverse drug reactions. The appropriate use, storage and
disposal of medicines should be ensured in order to minimize
adverse events.
8.2.6. Individualizing drug and dosage requirements
The CF Clinical Pharmacist should aim, whenever possible, to
maximize the therapeutic potential and minimize the adverse
effects of medicines. Therapeutic drug monitoring of specific
medicines (e.g. aminoglycosides, azoles) according to an
individual's pharmacokinetic variables and monitoring and
reviewing the outcome of an individual's need for medication are
also required. While optimizing the use of medicines the CF
Clinical Pharmacist also needs to take into account the patient's
wishes and lifestyle.
The CF Clinical Pharmacist needs to keep up to date with
newly available medications and therapies (e.g. new nebulized
antimicrobials), and find a place for them in the treatment regimen.
8.2.7. Educating and counselling patients and carers
The CF Clinical Pharmacist has an important role to play in
providing appropriate patient education and counselling to ensurethe safe and effective use of medicines. This may include patient
information leaflets about medicines and other appropriate
methods of improving adherence to treatment. Pharmacists
should also agree an informed plan with a patient/carer to
achieve the best possible concordance with medication.
8.2.8. Evaluating medicine use
The CF Clinical Pharmacist's non-clinical responsibilities
will include financial reporting to the CF MDT, hospital
management, and other authorities, as appropriate, on CF
medication usage. They should audit treatment guidelines, new
therapies and homecare services.
9. Framework for psychosocial care
Living with CF provides many challenges for patients and
their families. The CF Centre should provide adequate psycho-
social care and support to help the person with CF and the
families meet these challenges. In order to deliver optimal care
CF Centres need a multidisciplinary framework to include access
to psychosocial professionals throughout the patient's life. The
core psychosocial professionals available should be a Clinical
Psychologist and a Social Worker, though variations on these
professions are acceptable provided core competencies are met
(see below). Psychosocial professionals should be proficient
in the following areas: working with children, families and
adults according to the needs of the specific CF Centre; working
with patients presenting with a range of clinical severity; and
delivering care in all CF settings including outpatients, inpatients,
community and residential care.
The variability of patient needs and availability of expertise
in CF Centres prevent the formulation of a single programme.
Psychosocial care should be provided within the context of the
patients' development: from infancy to toddler, childhood,
adolescence, young adulthood, adult life and old age. In each
stage there are age-related themes as well as CF themes [69,70]
(Table 3). Key stages include the time around diagnosis [71],
the transition to adult care [19,72–76] and the transition to
end-of-life/transplantation care [77,78]. The disease trajectory
itself also necessitates times of increased psychosocial support,
for example, at diagnosis, first P. aeruginosa infection, first
inpatient admission, diagnosis of CF-related diabetes, the need for
gastrostomy tube feeding, supplementary oxygen, non-invasive
ventilation, and assessment for lung transplantation. Psychosocial
professionals should be included in the multidisciplinary care at all
of these stages (Table 3).
9.1. The CF social worker
9.1.1. Role
The CF Social Worker provides expertise in helping patients
and families with their emotional and practical needs and
supports patients and families in coping with CF in the different
developmental and disease stages. The CF Social Worker should
bridge the gap between hospital life and home life and liaise with
locally available support so that local services can be accessed.
The CF Social Worker is actively involved in the different
Table 3
Examples of important life events where psychosocial support is crucial in people with cystic fibrosis.
Childhood years Adolescent years Adult years
Starting kindergarten/day care/pre-school Starting secondary school Starting higher education
Starting school Being a teenager with CF Starting to work
First awareness of being different First relationship Starting a long-term relationship
Eating problems First sexual experience Parenthood
Sleeping problems Death of a CF friend Death of a CF friend
Behavioural problems (e.g. non-adherence) Behavioural problems (e.g. non-adherence) Behavioural problems (e.g. non-adherence)
Examples of key medical stages
CF diagnosis Diagnosis of infertility
First Pseudomonas infection Treatment of infertility
First episode of allergic bronchopulmonary aspergillosis Awareness of deteriorating disease
Gastrostomy placement Transition to the adult clinic
Diagnosis CF-related diabetes Transition to transplantation
First haemoptysis and other complications Transition to end-of-life care
Supplementary oxygen dependence Transplantation
CF, cystic fibrosis.
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to transplantation care (Table 3). The CF Social Worker has an
expertise that complements that of the CF Clinical Psychologist.
The CF Social Worker must have skills in the assessment of
practical needs and provide a range of services that are available
in the patient's country. Up-to-date knowledge of the country's
system of benefits and allowances is essential. The CF Social
Worker has to be able to liaise with other agencies (e.g. health
insurance companies, child benefit agencies, social welfare
agencies, hospital administration, school, CF patient associa-
tions) and serve as an advocate for patients and families. The CF
Social Worker must have expertise in educational and career
issues of the country where the patient resides. They should be
skilled in the implementation of child protection procedures, and
ensure effective information sharing, referral and liaison to home
authority teams, where appropriate. Home visits can greatly
contribute to best care and should be available where needed.
9.1.2. Professional development
CF Social Workers need to keep up to date with changes in
healthcare systems, financial or social security matters, educational
and work aspects, and patient and family welfare concerns. CF
Social Workers need continuous education about CF issues. They
should attend national and international conferences regularly to
maintain up-to-date knowledge about CF and new scientific
developments.
9.2. The CF Clinical Psychologist
During their life people with CF have to acquire specific
CF-related healthcare behaviours in conjunction with acquiring
normal developmental tasks. The CF Clinical Psychologist can
help patients and families with these challenges and support
them in coping with CF and its treatment throughout life.
9.2.1. Role
In relation to the patient and the family, the key responsibil-
ities of the CF Clinical Psychologist are the assessment of,
and intervention in, emotional, behavioural and psychologicaldifficulties, using evidence-based treatments where indicated and
making onward referrals where appropriate. The CF Clinical
Psychologist is responsible for all the psychological work in the
CF Centre. They should offer outpatient clinics as well as caring
for hospitalized patients. Adherence, eating behavioural prob-
lems, anxiety and depression, demoralization, pain, phobias and
sleep are day-to-day themes that need psychological care.
The CF Clinical Psychologist may use mediation techniques
in working with other CF MDT members. In addition, the CF
Clinical Psychologist should provide a consultation and super-
vision service to other members of the CF MDT in their work
with patients, and provide staff support in coping with ‘working
in CF’.
The CF Clinical Psychologist must be registered with their
national governing body. They should have expertise in child/
adolescent and/or adult clinical psychology and also in systemic
psychology and the psychology of grief and bereavement. The
CF Clinical Psychologist must be skilled in applying therapeutic
techniques that have proven efficacy in patients and families
with CF. These include, for example (cognitive) behavioural
techniques [79,80] and motivational interviewing [81]. Finally, the
CF Clinical Psychologist has to be up to date with research on
psychological issues in CF, including adherence, self-management
and self-care, impact of chronic illness on human development,
impact of chronic illness on family and social life, end-of-life
issues and palliative care. The CF Clinical Psychologist should
have or should develop, skills and experience in conducting
psychological research with the aim of improving the care of
patients and the understanding of psychosocial issues in CF.
9.2.2. Professional development
CF Clinical Psychologists have a responsibility to engage in
CPD and in some countries this will be assessed as part of
annual registration. Clinical Psychologists working in CF have a
responsibility to update their knowledge of medical aspects
of CF as well as mental health. Some countries have a national
body for psychosocial professionals, such as in the UK, and
membership is a requirement of practising in a CF team. CF
Clinical Psychologists should attend national and international
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aware of scientific developments.
9.3. Facilities and requirements for psychosocial care
The CF Clinical Psychologist and the CF Social Worker need
sufficient time, office space, and facilities, and the support and
respect of the CFMDT. The CF SocialWorker and the CFClinical
Psychologist often need to stay in regular contact with patients and
families in between clinic visits and therefore need access to
modern media (e.g. email, phone, texting). They both need an
up-to-date interactive referral system to external psychosocial
professionals and institutions in order to provide problem-specific
psychosocial/mental healthcare (e.g. for attention deficit hyperac-
tivity disorder or autism) within the vicinity of a patient's home.
The CF Clinical Psychologist and CF Social Worker must
participate and contribute to the MDT meetings, decision making
and patient consultation.
10. Framework for clinical genetics
Clinical Geneticists, Medical Molecular Genetic Laboratory
Specialists and Genetic Counsellors have an increasingly
important role in the complex diagnosis and disease management
of CF, particularly in the areas of disease diagnosis, informed
reproductive choices and the assessment of disease liability of
CFTR variants detected by DNA sequencing. Furthermore, the
Clinical Geneticist assesses the linkage phase through family
segregation analysis, and ensures that complex alleles (which
may be associated with variable CF phenotype) are not under- or
misdiagnosed.
The Genetic Counsellor or the Clinical Geneticist provides
counselling on reproductive options to the families of newly
diagnosed children and to adult patients, and facilitates identifica-
tion of at-risk family members who are genetically related to the
patient.
Clinical Geneticists, working within the CF Centre, also
coordinate data sharing with specialized registries (e.g. the ECFS
Registry) and submission of detectedCFTRmutations to both the
Cystic Fibrosis Mutation Database (CFTR1), which serves as a
locus-specific database for mutations and variants identified on a
world-wide scale, and the Clinical and Functional Translation of
CFTR online interactive resource (CFTR2), in order to
objectively substantiate the disease liability of identified CFTR
gene variants.
If administration of CFTRmodulating therapies is considered,
the CF Clinical Geneticist is responsible for the laboratory
verification of the CFTR genotype in eligible patients (optimally
by independent sampling and DNA sequencing) and that the
laboratory examination is performed in an ISO 15189-accredited
laboratory that assures appropriate turn-around time.
11. Framework for data collection
CF is a multisystem clinically heterogeneous disease
with variable outcomes despite its monogenic origins. Although
phenotypic variation is influenced by genotype, siblings with thesame genotype differ in outcome suggesting the influence of
other factors such as modifier genes, the environment, airway
microbiota, social class, sex, access to healthcare and adherence
to treatment [82]. Collecting data at a national and international
level remains a key process to aid the understanding of the
epidemiology and outcomes of the disease. It is only through
accurate data collection that disease progression, outcomes,
health economics and the need for change can be identified [7].
High-quality data can also be used by policy makers to focus on
and prioritize future strategies and interventions.
CF is a relatively rare disease with small patient numbers.
Collecting data from a single institution limits the level at which
clinical and translational research can be undertaken, and does
not capture the significant variability in geographical outcome
[83]. It is therefore essential that both small and large CF units
submit data at least annually to national and/or European CF
registries in order to ensure that appropriate longitudinal data are
collected. The registry also acts as a monitor for an individual
Centre's outcomes, providing an additional tool for ensuring
standards of care and appropriate clinical governance.
Healthcare professionals can find collecting and submitting
data to national registries laborious and time consuming. Every
effort should be made to ensure that data sets are limited to those
of predictive value and that individuals can upload data through a
secure intuitive interface. Funders must ensure that larger
CF Centres have the resource to employ either a data clerk or
alternative individual whose ring-fenced responsibilities include
national data submission. To have value, such a personmust have
meaningful access to the management structure so that their voice
counts and they can submit gold standard data.
There is a need for the international CF community to adopt a
standard coding structure. Creating uniform clinical terminolo-
gies and classifications of disease through a primary coding
structure would allow clinical data to be mapped and shared
between registries as well as other data sets. The changes would
result in a common digital language allowing effective interna-
tional collaboration and would remove key barriers to electronic
connectivity.
Addressing this issue is a matter of urgency, as a new era of
medical informatics and electronic health records is upon us.
Health services have started to successfully deploy electronic
patient records, which automate the capture of data and have
the potential to feed large continuous data sets directly into
national and international registries. In Europe, a standard
called XML has been adopted as a first step to harmonizing
data from national registries. Almost all national organisations
follow this initial standard, but this is only a first step in order to
standardise the uploading; if the data collected do not adhere to
common unequivocal definitions, the XML format cannot
correct it. Therefore, common definitions and coding in both
national registries and directly reporting individual centres are
crucial.
The European Commission has decided to start funding a
European Platform on Rare Diseases Registration, which will
provide services and tools for the existing and future rare
diseases registries, in accordance with the Council Recommen-
dation on action in the field of rare diseases (2009/C 151/02).
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minimum outlay, which is a key given the difficult financial
situation in healthcare. Adopting a detailed coded registry structure
can have the added advantage of reducing costs and improving
productivity [84,85]. All such European and/or international data
aggregations will have to make the best possible use of local/
regional/national data acquisition and storage and intelligent ways
of data sharing or retrieval will have to be developed.
Registries are here to stay and should be seen as a key part of
any chronic disease management.
12. Challenges relating to developing health services in low
income countries
The aim of the ECFS Standards of Care Guidelines is to
improve the quality of care for patients with CF and to establish
best practice across the whole of Europe. Immediate implemen-
tation of these guidelines may prove difficult for less econom-
ically advantaged countries where CF services are absent or
inadequate. The EU EuroCareCF European Commission 6th
Framework Coordination Action project identified a persisting
wide difference in the standards of care across Europe, with some
Eastern European countries having very basic or no recognizable
CF services [7]. The likely reason for such dramatic inequalities
has been the absence of appropriate funding, a lack of staff
recruitment and training, and also a lack of political prioritization.
The current situation in Eastern Europe was assessed from
the responses to a questionnaire distributed to most Eastern
European countries by the ECFS Standards of Care Committee.
The aims were to evaluate:
• a minimum number of patients who attend CF Centres in
Eastern Europe
• national recognition of CF Centre networks, and
• the composition of CF MDTs and the cooperation between
paediatric and adult Centres.
Each question was answered on the basis of the current
situation in the country and in relation to the ECFS Standards of
Care [4]. The response rate was 44% (7/16: Czech Republic,
Hungary, Latvia, Poland, Serbia, Slovakia, Ukraine).
The major observations were as follows. While the number
of patients per CF Centre is currently below 50 in some Eastern
European countries, a requirement for a minimum number of
50 was seen to be an achievable goal. Centralized CF care has
been endorsed by government authorities in only three of seven
Eastern European countries. A paediatrician/pulmonologist,
a physiotherapist and a CF nurse specialist were agreed to be
essential team members. Many CF Centres lack a full-time CF
nurse specialist, a dietitian, a microbiologist, a psychologist, a
social worker or secretarial support. Collaboration between
paediatric Centres and those for adults with CF had not been
established in two of the countries that replied to the survey.
It is imperative that all European countries should strive to
implement best practice in accordance with the ECFS recom-
mendations. An initial stepwise approach may be needed in some
low income countries where there are no established services andCF MDTs virtually do not exist. For example, initial recruitment
of core medical, nursing and physiotherapy staff may be the most
appropriate initial investment on the way to establishing a service
that meets all ECFS standards. It is no longer acceptable to have
such dramatic variation in the survival of people with CF across
European nations, and every effort must be made to deliver
equality and high standards of care.
CF care in low income countries should be centralized in
well-established CF Centres that can guarantee a reasonable
standard of complex care for both paediatric and adult patients.
The Centre should care for at least 100 patients, although a
minimum of 50 may be temporarily considered acceptable.
Because of the financial and staffing limitations in Eastern
Europe, shared care with local hospitals is not a preferred
model of care. Resources should be directed at establishing
state-of-the-art CF care at a national level by the development
of specialized CF Centres at major hospitals, and where
possible at the level of University Hospitals. The minimum
staff requirements for a specialist CF team include a physician
and a specialist nurse (one each for children and adults in
Centres that care for all age groups), and a CF specialist
physiotherapist. The goal is to develop teams that include a
microbiologist, dietitian, psychologist, social worker and
clinical geneticist. Meanwhile the absence of these specialists
should not delay the setting up of regional CF Centres. Their
roles may be temporarily performed by specialist consultants of
the hospital who can be accessed by the CF service, even
though not primarily allocated to a CF team and therefore not
able, for instance, to participate in regular CF MDT meetings.13. Perspective from European CF associations
13.1. The function and role of national CF patient organisa-
tions in Europe
Most European countries have their own national CF patient
organisation. These vary in size and methodology but have one
thing in common: they fight for the interests of people with CF,
in the broadest sense of the word. They work together with
volunteers, who are often experts in CF but who may be
non-medical. In Europe patient organisations are developing
their own in-house expertise and employing professional staff,
for example in the area of healthcare quality, scientific research,
communication, fund raising, information provision, and the
legal and psychosocial aspects of CF. The organisations aim to
support patients and their parents, both individually and
collectively, and to define research agenda, to finance scientific
research and to test healthcare quality. They are often closely
involved in the setting up and maintenance of guidelines for the
diagnosis and treatment of CF.
The national CF organisation can play an important role
in the national CF registry. Many have helped found these
registries and continue to support and finance them. In a number
of countries, the CF organisation plays a role in the set-up and
organisation of research networks and healthcare quality
improvement programmes for people with CF.
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organisations to successfully achieve the above aims. Over the
past few years, CF organisations in countries such as the UK,
Germany, Belgium, France, Italy and The Netherlands have
invested millions of Euros in scientific research and healthcare
quality. As a result, they have made important contributions to
the progress that has been made in many healthcare areas of CF.
Patient participation is an important part of the work achieved
by patient organisations, as it is exactly the patients' perspective
that can and should be expressed by the national CF organisations.13.2. National organisations
The national CF organisations have responsibilities to
provide information. This material, which is made available to
people with CF and their parents/carers, is often developed in
collaboration with the CF Centres and covers all aspects of life
with CF: diagnosis, treatment, growing up with CF, raising a
child with CF, going to school with CF and building a life with
CF. National CF groups should work closely with CF Centres
in the organisation of healthcare, a cooperation that may vary in
its infrastructure in different countries. However, in all cases,
representatives of those Centres should be present on medical
advisory boards and scientific councils.
CF organisations should organise meetings for parents and,
with the use of information technology to safeguard against
cross-infection risks, for the patients themselves. E-health has
many advantages and is a subject that is being researched and
developed.
CF organisations are the obvious parties to represent
and protect the interests of patients and their parents/carers,
for example by supporting ready availability of new medica-
tions, securing reimbursements for medication and access to
high-quality healthcare. CF organisations should lobby and
exert pressure on the authorities, government and insurance
companies in this regard. They should also organise con-
gresses, symposia and other meetings (in collaboration with or
under the supervision of the healthcare organisations), in which
the specific (scientific) aspects of CF are discussed.
CF patient organisations are non-medical yet through close
cooperation with CF Centres have developed a lot of CF
expertise. It is important that the Centres and the organisation
exchange information on a regular basis in order to facilitate a
proactive approach to developments in the healthcare industry
and scientific research. This collaboration will help to improve
communication with patients, facilitating their inclusion in
scientific studies and solving problems on a national level more
swiftly.13.3. European organisations
The European CF patient organisations are united in a single
European society — CF Europe (CFE). The importance of
collaboration in Europe is growing, especially with regard to
healthcare access, which is not uniform, or even available, in all
European countries. As a result, collaboration in the fields ofresearch, research financing and fund raising is continually
increasing.
The European collaboration should lead to the CF organisations
in countries where CF healthcare is already at a high level
accepting their responsibility and offering their expertise to
countries in which adequate healthcare, access to healthcare and
the ready availability of medication are not universal. This should
take place in close collaboration with the CF Centres. Collabora-
tion through CF Europe has made it easier to lobby effectively on a
European level with regard to subjects such as organ donation,
accessibility, quality and affordability in healthcare.
Another level of European collaboration is partnering with the
European overarching patient support organisation (Eurordis),
which is representing the majority of rare disease national and
regional organisations (including CF) in e.g. terms of awareness
building, access to care, reimbursement policies, development of
European guidelines for centre care fundraising, introduction of
orphan medicinal products into therapy, including training
courses on various aspects of patient advocacy.
CF patient organisations are working increasingly with the
ECFS, for example by participating in the executive boards of the
EFCS Patient Registry and the EFCS Clinical Trials Network.
The latter is financially supported by a number of patient
organisations. Through the CF patient organisations, patients and
parents have become more involved recently in the assessment of
the ECFS Clinical Trials Network research protocols.Conﬂict of interest
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